CSG Maps Out a Munitions Production Surge as Polish Contracts Keep Piling Up
Published on 08/20/2026 at 14:12 | Redaktion boerse-global.de
The Dutch defence group CSG is laying down a steep production trajectory for its large-calibre ammunition lines, targeting 850,000 rounds annually by the end of 2026 and 1.1 million the following year. That compares with output of 550,000 units in 2025, underscoring how the company is betting on sustained European demand rather than a temporary procurement spike.
The expansion plan lands amid a flurry of contract announcements that have kept the stock in motion. Just over a fortnight ago, CSG signed a deal worth more than €100 million with Dezamet S.A., a subsidiary of Poland's Polska Grupa Zbrojeniowa, covering components for 155-mm artillery ammunition through 2029. Then, last Thursday, came the follow-up: contracts exceeding €150 million with Huta Stalowa Wola for hundreds of chassis destined for tactical multi-purpose vehicles.
Half-Year Numbers Provide the Backdrop
The capacity push rests on a solid operational foundation. On 7 August, CSG reported first-half 2026 revenue of €3.251 billion, up 17.2 percent year on year, with operating EBIT of €784 million translating into a 24.1 percent margin. Management reaffirmed its full-year guidance of €7.4 billion to €7.6 billion in sales at an EBIT margin between 24 and 25 percent.
Unlike vehicle or chassis orders, which touch the fringes of the business, the production expansion goes straight to the core of CSG's munitions franchise. The decision signals that management views the European demand environment as structural — a durable shift in defence procurement patterns rather than a short-lived cycle.
The half-year report also included the completion of a minority stake in North Vector Dynamics, adding another layer to the group's growth narrative.
While CSG scales up its industrial capacity to meet structural demand, manufacturers in every sector face a different kind of compliance pressure — keeping workplace risk assessments legally current. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay on the right side of UK health and safety law. Download the free Risk Assessment Toolkit
A Share Price Caught Between Momentum and Caution
The stock's recent run has been anything but smooth. On Thursday, shares traded at €19.09, down 2.1 percent from the previous close of €19.50. Yet the monthly picture tells a different story: a gain of 29 percent, though the price still sits 47 percent below its 52-week high of €36.05, reached in late January. The distance from the year's low of €12.20, set at the end of June, remains substantial.
Technical indicators point to a market that is warm but not overheated — the relative strength index stands at 65.4, suggesting room for further upside without flashing alarm signals.
Analysts, however, remain divided on valuation. RBC Capital Markets initiated coverage on 12 August with a "Sector Perform" rating and an €18.00 price target, acknowledging the strong munitions environment but judging the shares fairly priced relative to peers. Barclays took a more cautious stance, starting coverage with an "Underweight" after the recent rally. Berenberg raised its earnings estimates following the half-year results but simultaneously cut its price target — a sign that much of the operational upside may already be reflected in the share price. J&T Banka, by contrast, had begun coverage with a buy recommendation ahead of the results.
What Comes Next
Investors now have their eyes on 11 November, when CSG publishes its third-quarter trading update. That report should reveal whether the announced production ramp-up is already translating into the numbers — and whether the Polish order flow, which has been a steady drumbeat of contract wins, shows any signs of slowing.
As defence contractors scale up operations, the safety of workers on the factory floor becomes even more critical. Over 37,000 UK businesses already rely on a free Health & Safety Toolkit covering key regulations like COSHH and PUWER to protect their teams and avoid costly fines. Get the free Health & Safety Toolkit
For now, the picture is one of operational momentum meeting contested valuation. The Polish contracts, the capacity expansion, and the reaffirmed guidance all point to a company executing on its growth strategy. Whether the market's divergent analyst opinions resolve in favour of the bulls or the bears will likely depend on how quickly the new production lines come online and whether the order pipeline continues to deliver at this pace.
